A 53-year-old woman suffering from nausea and vomiting was admitted to our hospital. There was a large ulcer from her left anterior chest to her right side chest. After pathological examination from the ulcer, she was diagnosed as breast cancer, scirrhous carcinoma. The estrogen and progesterone receptors were positive in the tumor. HER2 score was 1+ in the tumor. The stage was T4bNxM1(OTH). Uterine metastases of the breast cancer caused obstructive nephropathy. Ureteral obstruction was treated by urinary tract catheter. After improvement of renal failure, chemotherapy with 5-FU+epirubicin+cyclophosphamide (FEC) and docetaxel was performed. The efficacy was judged as stable disease (SD). For third-line chemotherapy, she was then treated with oral combination chemoendocrine therapy with capecitabine and medroxyprogesterone acetate. After the combination chemoendocrine therapy, the local tumor was remarkably reduced. With added cyclophosphamide, the partial response (PR) continued for 19 months. She died of peritonitis carcinomatosa and pleuritis carcinomatosa. No adverse reactions occurred with the combination chemoendocrine therapy. It is suggested that this oral combination chemoendocrine therapy may be useful with consideration for treatment effectiveness and the quality of life of the patient.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study.
Lancet Oncol
December 2024
British Columbia Cancer Agency, Vancouver, BC, Canada.
Background: Alpelisib, a PI3Kα-selective inhibitor and degrader, plus fulvestrant showed efficacy in hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer in SOLAR-1; limited data are available in the post-cyclin-dependent kinase 4/6 inhibitor setting. BYLieve aimed to assess alpelisib plus endocrine therapy in this setting in three cohorts defined by immediate previous treatment; here, we report results from cohort A.
Methods: This ongoing, phase 2, multicentre, open-label, non-comparative study enrolled patients with hormone receptor-positive, HER2-negative, advanced breast cancer with tumour PIK3CA mutation, following progression on or after previous therapy, including CDK4/6 inhibitors, from 114 study locations (cancer centres, medical centres, university hospitals, and hospitals) in 18 countries worldwide.
Clinical characteristics and survival of patients with de novo metastatic prostate cancer treated with androgen deprivation therapy and taxane-based chemotherapy in Uganda: a retrospective study.
BMC Cancer
November 2024
Department of Medical Oncology and Hematology, Uganda Cancer Institute, Kampala, Uganda.
Article Synopsis
- - Prostate cancer is a major health issue globally, particularly in resource-limited settings like Uganda, where late-stage diagnosis contributes to high mortality rates.
- - A study at the Uganda Cancer Institute reviewed 300 patients with metastatic prostate cancer (mPCa) over five years, finding a significant drop in overall survival from 92.4% at one year to 45.2% at five years, with factors like high Gleason scores and fewer chemotherapy cycles linked to poorer outcomes.
- - Most patients experienced severe lower urinary tract symptoms and a high median prostate-specific antigen (PSA) level at diagnosis, indicating advanced disease, emphasizing the need for improved early detection and treatment strategies in such settings.
Prediction of menstrual recovery patterns in premenopausal women with breast cancer taking tamoxifen after chemotherapy: an ASTRRA Substudy.
Breast Cancer Res
November 2024
Division of Breast Surgery, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, South Korea.
Background: Chemo-endocrine therapy can lead to various side effects associated with ovarian dysfunction. Predicting menstrual recovery is necessary to discuss the treatment-related issues regarding fertility and premature menopause with patients.
Methods: In the ASTRRA trial, patients who resumed ovarian function within 2 years after chemotherapy were randomized to receive tamoxifen for 5 years or OFS with tamoxifen for 2 years.
Neoadjuvant Chemotherapy with Concurrent Letrozole for Estrogen Receptor-Positive and HER2-Negative Breast Cancer: An Open-Label, Single-Center, Nonrandomized Phase II Study (NeoCHAI).
Cancers (Basel)
September 2024
Department of Internal Medicine, Center for Breast Cancer, Hospital, National Cancer Center, 323 Ilsanro, Goyang 10408, Republic of Korea.
Article Synopsis
- A phase II trial was conducted to evaluate the effectiveness of combining letrozole (an endocrine therapy) with traditional chemotherapy in women with untreated stage II or III HR-positive, HER2-negative breast cancer.
- Out of 53 patients, only 2 (4%) achieved a pathologic complete response (pCR), which was below the necessary threshold to continue the trial, though the overall response rate was high at 83%.
- The treatment was deemed safe, with a 3-year disease-free survival rate of 87% and no deaths during treatment, but it did not significantly improve pCR rates, indicating the need for further research on neoadjuvant therapies for this cancer type.
[A Long-Surviving Case of Locally Advanced Breast Cancer with Multiple Lung Metastasis].
Gan To Kagaku Ryoho
April 2024
Dept. of Surgery, Tokyo Metropolitan Ohkubo Hospital.
We report a case of right advanced breast cancer with multiple lung metastases in a 66-year-old woman. Her breast cancer( invasive ductal carcinoma, cT4bN1M1, Stage Ⅳ)was resected in October 2007(mastectomy plus axillary lymph node dissection)after local arterial infusion therapy(total dose 5-FU 4,735 mg plus adriamycin 180 mg), which caused bilateral lung arterial embolism due to deep vein thrombosis in right her leg. She had to be treated by anticoagulant therapy, mechanical ventilation and placement of IVC filter before her operation.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!